Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Verve Therapeutics, Inc.

http://www.vervetx.com

Latest From Verve Therapeutics, Inc.

Beam Therapeutics’ Base-Edited CAR-T Placed On Hold

Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.

Companies Clinical Trials

Vertex Expands In Vivo Gene-Editing Plans With Verve Liver Disease Pact

Vertex is expanding its investments across advanced therapies again, R&D chief David Altshuler adding a second in vivo gene-editing deal to its pipeline.

Commercial Companies

Verve Hits The Clinic With Gene-Edited Cholesterol-Lowering Drug

The company dosed the first patient in its study of base editor VERVE-101, a possible single-dose treatment for HeFH that joins a growing list of PCSK9-targeted therapy candidates.

Gene Therapy Clinical Trials

AstraZeneca and Ionis Think They Have A Best-In-Class PCSK9 Challenger To Novartis’s Leqvio

AstraZeneca and Ionis believe they have a potential best-in-class PCSK9 inhibitor, but the product will have to impress in forthcoming pivotal trials to catch up with Novartis’s Leqvio.

Companies Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register